Skip to main content

1 Result(s)

within Eleonora Prete Remove this filter

and

  1. No Access

    Article

    Carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience of Rete Ematologica Pugliese (REP)

    Carfilzomib, lenalidomide, and dexamethasone (KRd) have been approved for the treatment of relapsed and refractory multiple myeloma (RRMM) based on ASPIRE clinical trial. However, its effectiveness and safety ...

    Anna Mele, Eleonora Prete, Clara De Risi, Stefania Citiso… in Annals of Hematology (2021)